Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0516 Monotherapy and Combination Therapy in Metastatic Prostate Cancer
NCT07181161Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2025
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of AZD0516 in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with Adverse Events, Serious Adverse Events and Adverse Event of Special Interests at 3 years, Number of participants with Dose Limiting Toxicities at 21 days and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
AZD0516
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07181161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181161.